- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
10 result(s) found for: Ageusia.
Displaying page 1 of 1.
| EudraCT Number: 2020-001455-40 | Sponsor Protocol Number: GRECCO-19 | Start Date*: 2020-04-01 | |||||||||||
| Sponsor Name:Hellenic Society of Rhythmology | |||||||||||||
| Full Title: The Greek study in the Effects of Colchicine in Covid-19 complications prevention | |||||||||||||
| Medical condition: This trial will investigate if colchicine could potentially have an effect in patients’ clinical course by limiting the myocardial necrosis and pneumonia development in the context of COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005523-37 | Sponsor Protocol Number: BromCO | Start Date*: 2021-06-21 | |||||||||||
| Sponsor Name:URSAPHARM Arzneimittel GmbH | |||||||||||||
| Full Title: A prospective controlled proof-of-concept trial to demonstrate anti-viral effects of oral bromelaine in COVID-19 positive patients | |||||||||||||
| Medical condition: Diagnosis of SARS-CoV-2 infection documented by a positive PCR test | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000605-24 | Sponsor Protocol Number: ESPERANZA_COVID | Start Date*: 2021-07-08 | |||||||||||
| Sponsor Name:IDIAP Jordi Gol | |||||||||||||
| Full Title: Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID: E-SPERANZA COVID PROJECT | |||||||||||||
| Medical condition: Patients with a history of SAR-Cov-2 infection (PCR positive) with long Covid-19 and mild or moderate respiratory symptoms of more than 1 month and less than 4 months of evolution, attended in Prim... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001697-30 | Sponsor Protocol Number: COVIDNA | Start Date*: 2020-04-23 |
| Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET | ||
| Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) | ||
| Medical condition: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000166-15 | Sponsor Protocol Number: IVM-2021-01 | Start Date*: 2021-03-03 |
| Sponsor Name:Meditop Gyógyszeripari Kft | ||
| Full Title: A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients | ||
| Medical condition: COVID 19 infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000045-41 | Sponsor Protocol Number: TEE001DP-01 | Start Date*: 2021-06-08 | |||||||||||
| Sponsor Name:Institut Pasteur de Lille | |||||||||||||
| Full Title: Adaptive, Ambulatory, Randomised, Placebo-Controlled, Double-Blind, Phase 2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of TEE001DP in Patients at the Early Stage of Symptomatic COVI... | |||||||||||||
| Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005544-34 | Sponsor Protocol Number: CARVIN | Start Date*: 2021-02-04 | |||||||||||
| Sponsor Name:URSAPHARM Arzneimittel GmbH | |||||||||||||
| Full Title: Double-blind placebo-controlled proof-of-concept trial to demonstrate the anti-viral efficacy of different doses of azelastine in COVID-19 positive patients. | |||||||||||||
| Medical condition: Diagnosis of SARS-CoV-2 infection documented by a positive PCR test (patients do not need to suffer from COVID-19 symptoms) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001673-75 | Sponsor Protocol Number: ABX464-401 | Start Date*: 2020-05-06 |
| Sponsor Name:ABIVAX | ||
| Full Title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu... | ||
| Medical condition: COVID-19 infection (infection with SARS-CoV-2 virus) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003102-26 | Sponsor Protocol Number: HIV-CORE007 | Start Date*: 2021-07-14 | |||||||||||
| Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
| Full Title: Therapeutic vaccination: A Phase I/II Randomized, Placebo-Controlled Trial of ChAdOx1.tHIVconsvX prime-MVA.tHIVconsvX Boost Vaccination Regimen in Early-treated durably-controlling HIV-1 positive A... | |||||||||||||
| Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005226-28 | Sponsor Protocol Number: D8110C00001 | Start Date*: 2021-01-22 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for ... | |||||||||||||
| Medical condition: SARS-COV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.